Blackman Samuel C. 4
4 · Day One Biopharmaceuticals, Inc. · Filed Aug 19, 2024
Insider Transaction Report
Form 4
Blackman Samuel C.
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-08-16$14.00/sh−2,232$31,246→ 1,127,535 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2024-08-15−1,187→ 5,943 total→ Common Stock (1,187 underlying) - Exercise/Conversion
Common Stock
2024-08-15+1,187→ 1,122,268 total - Exercise/Conversion
Common Stock
2024-08-15+1,437→ 1,123,705 total - Exercise/Conversion
Common Stock
2024-08-15+6,062→ 1,129,767 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2024-08-15−1,437→ 12,941 total→ Common Stock (1,437 underlying) - Exercise/Conversion
Restricted Stock Unit (RSU)
2024-08-15−6,062→ 78,814 total→ Common Stock (6,062 underlying)
Holdings
- 1,000,000(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
- [F3]The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.
- [F4]The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.